BRIEF published on 09/24/2024 at 23:05, 1 year 10 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 10 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 10 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 10 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 10 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 10 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 11 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 11 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 11 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 11 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 08/01/2026 at 01:20, 2 days 8 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 8 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 9 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 2 days 10 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/03/2026 at 09:18, 34 minutes ago Conference call on the results for the 3rd quarter 2025/2026 (ending 30 June 2026) on 12 August 2026
Published on 08/03/2026 at 08:29, 1 hour 23 minutes ago Launch of a €225 million tranche of its share buyback programme
Published on 08/03/2026 at 07:00, 2 hours 52 minutes ago BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 12 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 14 hours ago Share retention commitments (Dutreil Agreement)
